There were low and statistically similar 1-year death rates in the enoxaparin groups (0.5mg/kg or 0.75 mg/kg) and UFH during and after elective percutaneous intervention (PCI). In addition to patient risk factors, ischemic events and major bleeding were found to be independent predictors of death at 1 year.
Commenting on the results, Dr. Gilles Montalescot who is Professor of Cardiology at the Institute of Cardiology, Hopital de la Pitie Salpetriere, Institut du Coeur, Paris, France and a member of the STEEPLE steering committee noted, "The significant reduction in major bleeding and similar efficacy compared with UFH confirms Lovenox(R) is an appropriate anticoagulant for elective PCI."
About Coronary Artery Disease (CAD) and Acute Coronary Syndrome (ACS)
Coronary artery disease (CAD) is the most common type of heart disease globally and is a serious health problem worldwide. CAD causes approximately 17 million deaths per year: the equivalent of one out of every three deaths worldwide. According to the American Heart Association, more than 13 million Americans have a history of CAD and 7.5 million have experienced an acute heart attack.
Acute coronary syndrome (ACS) is an umbrella term used to describe a group of clinical diagnoses caused by narrowing of the coronary arteries and cover any group of clinical symptoms compatible with acute myocardial ischemia, caused by an imbalance between myocardial oxygen supply and demand that results from CAD.
Immediate treatment is required for all ACS. The treatment approach is
multifaceted and aims to try and protect the affected heart muscle from
further damage, reinstate blood flow
Copyright©2007 PR Newswire.
All rights reserved